Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies

Journal of Clinical Oncology

Volumn 23, Issue 17, 2005, Pages 3906-3911

  Rudek, Michelle A ^a   Zhao, Ming ^a   He, Ping ^a   Hartke, Carol ^a   Gilbert, Jill ^a   Gore, Steven D ^a   Carducci, Michael A ^a   Baker, Sharyn D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZACITIDINE; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; CYTIDINE DERIVATIVE; DNA METHYLTRANSFERASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; LIQUID CHROMATOGRAPHY; MYELODYSPLASTIC SYNDROME; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; TANDEM MASS SPECTROMETRY; UNSPECIFIED SIDE EFFECT; BIOAVAILABILITY; BLOOD DISEASE; DRUG ADMINISTRATION; DRUG COMBINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLIC CLEARANCE RATE; METABOLISM; TUMOR RECURRENCE;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HEMATOLOGIC NEOPLASMS; HUMANS; METABOLIC CLEARANCE RATE; NEOPLASM RECURRENCE, LOCAL; PHENYLBUTYRATES;

EID: 21244447049     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.07.450     Document Type: Article

References (19)

1. Carducci MA, Gilbert J, Herman J, et al: Clinical trials with HDAC and DNA methylation inhibitors. Clin Cancer Res 7:3829s-3830s, 2001 (suppl)
2. Claus R, Lubbert M: Epigenetic targets in hematopoietic malignancies. Oncogene 22: 6489-6496, 2003
3. Gilbert J, Gore SD, Herman JG, et al: The clinical application of targeting cancer through histone acetylation and hypomethylation. Clin Cancer Res 10:4589-4596, 2004
4. Pharmion's Vidaza approved in US to treat MDS: Retracts EU thalidomide application. Cancer Drug News 122:8, 2004
5. Notari RE, DeYoung JL: Kinetics and mechanisms of degradation of the antileukemic agent 5-azacytidine in aqueous solutions. J Pharm Sci 64:1148-1157, 1975
6. Kissinger LD, Stemm NL: Determination of the antileukemia agents cytarabine and azacitidine and their respective degradation products by high-performance liquid chromatography. J Chromatogr 353:309-318, 1986
7. Rustum AM, Hoffman NE: High-performance liquid Chromatographic determination of 5-azacytidine in plasma. J Chromatogr 421:387-391, 1987
8. Zhu WG, Lakshmanan RR, Beal MD, et al: DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 61:1327-1333, 2001
9. Cameron EE, Bachman KE, Myohanen S, et al: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103-107, 1999
10. Zhao M, Rudek MA, He P, et al: Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 813:81-88, 2004
11. Gore SD, Baylin SB, Carducci MA, et al: Sequential DNA methyltransferase and histone deacetylase inhibition to re-express silenced genes: Pre-clinical and early clinical modeling. Proc Am Assoc Cancer Res 42:681, 2001
12. Wittes R: Manual of Oncologic Therapeutics. Philadelphia, PA, Lippincott, 1991
13. Zhao M, Newman EM, Doroshow JH, et al: Sensitive and specific method for the determination of 5-aza-2′-deoxycyticine in human plasma by LC-MS-MS. Proc Am Assoc Cancer Res 43:1067, 2002
14. Gibaldi M, Perrier D: Noncompartmental Analysis Based on Statistical Moment Theory, Pharmacokinetics (ed 2). New York, NY, Marcel Dekker, 1982, pp 409-417
15. Pittillo RF, Woolley C: 5-azacytidine: Microbiological assay in mouse blood. Appl Microbiol 18:284-286, 1969
16. Lomen PL, Baker LH, Neil GL, et al: Phase I study of 5-azacytidine (NSC-102816) using 24-hour continuous infusion for 5 days. Cancer Chemother Rep 59:1123-1126, 1975
17. Israili ZH, Vogler WR, Mingioli ES, et al: The disposition and pharmacokinetics in humans of 5-azacytidine administered intravenously as a bolus or by continuous infusion. Cancer Res 36:1453-1461, 1976
18. Troetel WM, Weiss AJ, Stambaugh JE, et al: Absorption, distribution, and excretion of 5-azacytidine (NSC-102816) in man. Cancer Chemother Rep 56:405-411, 1972
19. Gore SD, Baylin SB, Dauses T, et al: Changes in promoter methylation and gene expression in patients with MDS and MDS-AML treated with 5-azacitidine and sodium phenylbutyrate. Blood 104:469a, 2004